Table 1.

Different approximations for the design of organelle-targeted MSNs.

Carrier Type	Organelle	Organelle Targeting Molecule	Drug	Cell Line(s)	In Vivo	Application	Ref
MSNs	Mitochondria	TPP	DOX	HeLa	X	Cancer	[77]
DMSNs		TPP	X	A549	X	Cancer	[78]
MSNs		TPP	X	HepG2	X	Cancer	[79]
Fe3O4@MSN		TPP	DOX	MGC-803, MCF-7	X	Cancer	[80]
MSNs		TPP	AIPH and DTX	MDA-MB-231	Mice	Cancer	[81]
MSNs		TPP	DOX	MGC-803	X	Cancer	[82]
Fe3O4@MSN		Guanidinium	DOX	HeLa	X	Cancer	[83]
AuNR@MSN		(RLARLAR)2	X	MCF-7	Mice	Cancer	[84]
MSNs		α-tocopheryl succinate	DOX	MCF-7	Mice	Cancer	[85]
MSNs		Celastrol	Celastrol	SCC-7,SH-SY5Y, BT-474	Mice	Cancer	[86]
MSNs		PAA	Umbelliferone	MCF-7	Mice	Cancer	[87]
MSNs		TPP, (KLAKLAK)2	Topotecan	HeLa	X	Cancer	[88]
MSNs		RGD-hylin a1	RGD-hylin a1	HeLa	Mice	Cancer	[89]
MSNs		Amino-T807	Methylene blue	SH-SY5Y	Mice	Alzheimer’s disease	[90]
MSNs	Nucleus	TAT	DOX	MCF-7	X	Cancer	[93]
MSNs		TAT	Plasmid	Hela	Mice	Cancer	[94]
MSNs		TAT	Camptothecin	HeLa	X	Cancer	[95]
MSNs		TAT	Topotecan	MDA-MB-231	Mice	Cancer	[96]
MSNs		TAT	Gemcitabine, doxorubicin	HeLa	Mice	Cancer	[97]